Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, Duke University School of Medicine, Durham, North Carolina.
Clin Obstet Gynecol. 2023 Mar 1;66(1):196-207. doi: 10.1097/GRF.0000000000000740. Epub 2022 Aug 10.
Increasing rates of thromboembolic complications have required increasing use of anticoagulant and antiplatelet agents during and after pregnancy. Furthermore, thromboembolism is both a cause and a complication of severe maternal morbidity requiring intensive care. As a consequence, almost all patients admitted to intensive care units receive an anticoagulant or an antiplatelet agent (or both) for either treatment or prevention of thromboembolism. In this review, we summarize commonly used anticoagulants and antiplatelet agents and outline the potential role of newly developed (novel) antithrombotic agents for pregnant and postpartum patients.
随着血栓栓塞并发症发生率的增加,在妊娠期间和妊娠后需要越来越多地使用抗凝和抗血小板药物。此外,血栓栓塞既是严重产妇发病率的原因,也是需要重症监护的并发症。因此,几乎所有入住重症监护病房的患者都因治疗或预防血栓栓塞而接受抗凝剂或抗血小板药物(或两者兼用)。在这篇综述中,我们总结了常用的抗凝剂和抗血小板药物,并概述了新型抗血栓形成药物在妊娠和产后患者中的潜在作用。